On June 24, Novo Nordisk rose 3.02% in regular trading, trading at $47.27/share, with turnover of $659 million.

On the news front, multiple positive catalysts continue to drive the stock higher. CEO Lars Fruergaard Jorgensen recently confirmed that semaglutide's regulatory data protection period in China will extend through April next year, approximately 13 months beyond the core compound patent expiration date. This extended protection window is estimated to generate roughly $1 billion in additional stable cash flow for the company.

During his first visit to China, the CEO also announced plans to submit oral Wegovy clinical data to Chinese regulators within months seeking marketing approval, while committing an additional 200 million RMB investment to expand injection pen assembly capacity in Tianjin. He further disclosed that Novo Nordisk will increase BD transactions in China, maintaining active dialogue with multiple Chinese companies. Internationally, oral Wegovy recently received UK regulatory approval with clinical data showing 13.6% average weight loss over 64 weeks, reinforcing the company's global GLP-1 commercialization outlook.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)